Heidelberg Pharma: Letter from the CEO

EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma: Letter from the CEO 17.12.2025 / 09:21 CET/CEST The issuer is solely responsible for the content of this announcement. Letter from the CEO Dear shareholders, partners, and friends of Heidelberg Pharma,

The past few months have been turbulent and difficult for Heidelberg Pharma. We have been confronted with events and changes that required swift and decisive action. Today, I am writing to you to explain where we stand - and, above all, why I am deeply convinced that the difficult path we have now embarked upon will be worthwhile.

The expected milestone payment for the approval of the kidney cancer imaging agent TLX250-CDx has been delayed because the FDA’s Complete Response Letter (CRL) to our our Partner Telix Pharmaceuticals has identified deficiencies in the Chemistry, Manufacturing and Controls (CMC) package with no clinical efficacy or safety concerns, noted in Telix’ communication. The medical potential of TLX250-CDx is undisputed, and we share our partner's assessment that this product will fundamentally change the diagnosis of kidney cancer, which will enhance the therapeutic efficacy. We have now reached an amicable agreement with Telix to ensure a constructive communication and work closely together with the aim to launch the product for the benefit of patients who need it.

To ensure the continued operation of the company, we launched a thorough cost-cutting program at the end of September. This includes the painful decision to part ways with 85 highly qualified and dedicated colleagues and to significantly adjust our science-oriented R&D capacities to the current financial reality. This tough business decision was taken after several long discussions and debates in the Management and Supervisory Board. We made this decision because there was no responsible alternative to saving the operational core of our company. On behalf of myself and my colleague on the Management Board Walter Miller, I would like to express my heartfelt thanks to the employees who have to leave us. Their dedicated and outstanding work has laid the foundation on which we can now continue to build.